Search research articles
Contact Us
Filters
Showing results (1-10 of 26) with videos related to
Page
of 3
Sort By:
Frontiers in Oncology
|
March 6, 2020
Modifying the Non-muscle Invasive Bladder Cancer Immune Microenvironment for Optimal Therapeutic Response
Nicola E Annels, Guy R Simpson, Hardev Pandha
Cancer Immunology, Immunotherapy : CII
|
November 17, 2011
Are we ready to start studies of Th17 cell manipulation as a therapy for cancer?
Gary W Middleton, Nicola E Annels, Hardev S Pandha
Journal of Clinical Pathology
|
January 21, 2022
Gene of the month: T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT)
Louisa Bolm, Natalie Petruch, Shivan Sivakumar, et al.
The Journal of Experimental Medicine
|
April 3, 2002
Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection
Andrew D Hislop, Nicola E Annels, Nancy H Gudgeon, et al.
Journal of Clinical Pathology
|
June 29, 2021
Gene of the month: lymphocyte-activation gene 3 (LAG-3)
Mark P Lythgoe, Daniel Si Kit Liu, Nicola E Annels, et al.
Cancer Immunology, Immunotherapy : CII
|
June 7, 2011
Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13
Rachel F Gabitass, Nicola E Annels, Deborah D Stocken, et al.
Trends in Immunology
|
April 17, 2003
Langerhans-cell histiocytosis 'insight into DC biology'
Jon D Laman, Pieter J M Leenen, Nicola E Annels, et al.
Expert Review of Gastroenterology & Hepatology
|
May 31, 2024
Is oncolytic adenoviral-mediated immunotherapy through p53-overexpression the solution to refractory pancreatic ductal adenocarcinoma?
Lucy J A Harriss, Lewis Stevens, Charles J Rayner, et al.
Molecular Therapy Oncolytics
|
March 5, 2021
Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors
Nicola E Annels, Guy R Simpson, Mick Denyer, et al.
Cancer Immunology, Immunotherapy : CII
|
November 8, 2023
The dysfunctional immune response in renal cell carcinoma correlates with changes in the metabolic landscape of ccRCC during disease progression
Nicola E Annels, M Denyer, D Nicol, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 26) with videos related to
Sort By:
Page
of 3
Frontiers in Oncology
|
March 6, 2020
Modifying the Non-muscle Invasive Bladder Cancer Immune Microenvironment for Optimal Therapeutic Response
Nicola E Annels, Guy R Simpson, Hardev Pandha
Cancer Immunology, Immunotherapy : CII
|
November 17, 2011
Are we ready to start studies of Th17 cell manipulation as a therapy for cancer?
Gary W Middleton, Nicola E Annels, Hardev S Pandha
Journal of Clinical Pathology
|
January 21, 2022
Gene of the month: T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT)
Louisa Bolm, Natalie Petruch, Shivan Sivakumar, et al.
The Journal of Experimental Medicine
|
April 3, 2002
Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection
Andrew D Hislop, Nicola E Annels, Nancy H Gudgeon, et al.
Journal of Clinical Pathology
|
June 29, 2021
Gene of the month: lymphocyte-activation gene 3 (LAG-3)
Mark P Lythgoe, Daniel Si Kit Liu, Nicola E Annels, et al.
Cancer Immunology, Immunotherapy : CII
|
June 7, 2011
Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13
Rachel F Gabitass, Nicola E Annels, Deborah D Stocken, et al.
Trends in Immunology
|
April 17, 2003
Langerhans-cell histiocytosis 'insight into DC biology'
Jon D Laman, Pieter J M Leenen, Nicola E Annels, et al.
Expert Review of Gastroenterology & Hepatology
|
May 31, 2024
Is oncolytic adenoviral-mediated immunotherapy through p53-overexpression the solution to refractory pancreatic ductal adenocarcinoma?
Lucy J A Harriss, Lewis Stevens, Charles J Rayner, et al.
Molecular Therapy Oncolytics
|
March 5, 2021
Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors
Nicola E Annels, Guy R Simpson, Mick Denyer, et al.
Cancer Immunology, Immunotherapy : CII
|
November 8, 2023
The dysfunctional immune response in renal cell carcinoma correlates with changes in the metabolic landscape of ccRCC during disease progression
Nicola E Annels, M Denyer, D Nicol, et al.
Page
of 3